Literature DB >> 8760877

Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency.

W M Flanagan1, A Kothavale, R W Wagner.   

Abstract

To understand the parameters required for designing potent and specific antisense C-5 propynyl-pyrimidine-2'-deoxyphosphorothioate-modified oligonucleotides (C-5 propyne ONs), we have utilized a HeLa line that stably expresses luciferase under tight control of a tetracycline-responsive promoter. Using this sensitive and regulatable cell-based system we have identified five distinct antisense ONs targeting luciferase and have investigated the role that ON length, target mismatches, compound stability and intracellular RNA levels play in affecting antisense potency. We demonstrate that C-5 propyne ONs as short as 11 bases retained 66% of the potency demonstrated by the parent 15 base compound, that a one base internal mismatch between the antisense ON and the luciferase target reduced the potency of the antisense ON by 43% and two or more mismatches completely inactivated the antisense ON and that C-5 propyne ONs have a biologically active half-life in tissue culture of 35 h. In addition, by regulating the intracellular levels of the luciferase mRNA over 20-fold, we show that the potency of C-5 propyne ONs is unaffected by changes in the expression level of the target RNA. These data suggest that low and high copy messages can be targeted with equivalent potency using C-5 propyne ONs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760877      PMCID: PMC146034          DOI: 10.1093/nar/24.15.2936

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  21 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

Authors:  J G Lewis; K Y Lin; A Kothavale; W M Flanagan; M D Matteucci; R B DePrince; R A Mook; R W Hendren; R W Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

3.  Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle.

Authors:  S Coats; W M Flanagan; J Nourse; J M Roberts
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

4.  The state of the art in antisense research.

Authors:  R W Wagner
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

5.  Antisense has growing pains.

Authors:  T Gura
Journal:  Science       Date:  1995-10-27       Impact factor: 47.728

Review 6.  Current concepts in antisense drug design.

Authors:  J F Milligan; M D Matteucci; J C Martin
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

7.  Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.

Authors:  R W Wagner; M D Matteucci; J G Lewis; A J Gutierrez; C Moulds; B C Froehler
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

8.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Authors:  C F Bennett; M Y Chiang; H Chan; J E Shoemaker; C K Mirabelli
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

9.  Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.

Authors:  B P Monia; J F Johnston; D J Ecker; M A Zounes; W F Lima; S M Freier
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

10.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

View more
  9 in total

1.  The spherulites(TM): a promising carrier for oligonucleotide delivery.

Authors:  N Mignet; A Brun; C Degert; B Delord; D Roux; C Hélène; R Laversanne; J C François
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

2.  Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.

Authors:  H J Andreyev; P J Ross; D Cunningham; P A Clarke
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.

Authors:  P Lorenz; B F Baker; C F Bennett; D L Spector
Journal:  Mol Biol Cell       Date:  1998-05       Impact factor: 4.138

4.  Inhibition of gene expression by anti-sense C-5 propyne oligonucleotides detected by a reporter enzyme.

Authors:  Y Hamel; J Lacoste; C Frayssinet; A Sarasin; T Garestier; J C François; C Hélène
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

5.  A cytosine analog that confers enhanced potency to antisense oligonucleotides.

Authors:  W M Flanagan; J J Wolf; P Olson; D Grant; K Y Lin; R W Wagner; M D Matteucci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Modulating Anti-MicroRNA-21 Activity and Specificity Using Oligonucleotide Derivatives and Length Optimization.

Authors:  Andrés Muñoz-Alarcón; Peter Guterstam; Cristian Romero; Mark A Behlke; Kim A Lennox; Jesper Wengel; Samir El Andaloussi; Ulo Langel
Journal:  ISRN Pharm       Date:  2012-02-07

7.  RNA major groove modifications improve siRNA stability and biological activity.

Authors:  Montserrat Terrazas; Eric T Kool
Journal:  Nucleic Acids Res       Date:  2008-11-28       Impact factor: 16.971

Review 8.  A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics.

Authors:  Kirsten Deprey; Nefeli Batistatou; Joshua A Kritzer
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

9.  A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy.

Authors:  Jeffrey M Keil; Joonbae Seo; Matthew D Howell; Walter H Hsu; Ravindra N Singh; Christine J DiDonato
Journal:  Mol Ther Nucleic Acids       Date:  2014-07-08       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.